Urologists on Twitter criticized high-intensity focused ultrasound and in some instances even mocked the treatment.
Urologists on Twitter criticized high-intensity focused ultrasound (HIFU) and in some instances even mocked the treatment.
Their comments came in response to a recent "Speak Out" article in which urologists discussed HIFU, as well as results from a Urology Times poll showing that 54% of respondents feel that HIFU has a future in the U.S. for treating prostate cancer. Declan Murphy, MB BCH, had a strong reaction to the poll results:
US urologists vote for HIFU @UrologyTimes. Have you all gone mad?? pic.twitter.com/VopwOPKyqr
- Declan Murphy (@declangmurphy) February 13, 2014
Other users mocked the treatment by joking about comical alternate uses for it:
@declangmurphy@daviesbj@UrologyTimes Could use it to warm coffee up I suppose #hifulatte
- Cycling Urologist (@KearsleyJamie) March 1, 2014
@declangmurphy@daviesbj HIFU machine would probably make a nice pot plant holder or prop for UFO movie ( anal probing etc ) #HIFUuses
- Cycling Urologist (@KearsleyJamie) March 1, 2014
Not everyone was completely negative about HIFU, however. Urologist Mutahar Ahmed, MD, of the New Jersey Center for Prostate Cancer & Urology, tweeted:
@UrologyTimes#prostatecancer#hifu. HIFU will have limited role in prostate cancer but may play bigger role in kidney cancer
- Mutahar Ahmed (@RoboticsUrology) January 1, 2014
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.